| COVID-19 |
1 |
0.97 |
| Biologic Therapy |
0 |
0.79 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.71 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.68 |
| HIV Infection |
0 |
0.68 |
| Scan |
0 |
0.31 |
| Severe Acute Respiratory Syndrome |
0 |
0.31 |
| Acute Respiratory Distress Syndrome |
0 |
0.27 |
| Mechanical Ventilation |
0 |
0.27 |
| Antiviral Agents |
0 |
0.2 |
| Corticosteroids |
0 |
0.2 |
| Cytokines |
0 |
0.2 |
| Monoclonal Antibody |
0 |
0.2 |
| Rheumatoid Arthritis |
0 |
0.13 |
| Adverse Effects |
0 |
0.1 |
| Arthritis |
0 |
0.1 |
| C-Reactive Protein (CRP) |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Hand |
0 |
0.1 |
| Health Care Quality, Access, and Evaluation |
0 |
0.1 |
| Immunization |
0 |
0.1 |
| Immunocompromise |
0 |
0.1 |
| Immunomodulator |
0 |
0.1 |
| Interleukin |
0 |
0.1 |
| Pandemic |
0 |
0.1 |
| Steroids |
0 |
0.1 |
| Tumor Necrosis Factor-Alpha |
0 |
0.1 |
| Patient Safety |
0 |
0.09 |
| Social Determinants of Health |
0 |
0.09 |